Tyler J. Wilhite, MD, discussed scaling low-dose radiation therapy for osteoarthritis from 1 patient to nearly 20 centers and the referral work behind it.
|Articles|August 24, 2009
Oncology NEWS International
- Oncology NEWS International Vol 18 No 8
- Volume 18
- Issue 8
Yaupon locks up phase II Clearazide trial
Yaupon Therapeutics has completed enrollment for the second phase of its trial for Clearazide for early-stage cutaneous T-cell lymphoma.
Advertisement
Yaupon Therapeutics has completed enrollment for the second phase of its trial for Clearazide for early-stage cutaneous T-cell lymphoma.
The randomized study, slated for completion in 2010, has enrolled 260 patients from 13 cancer centers. Clearazide is a topical form of nitrogen mustard, an alkylating agent that works by inhibiting DNA replication.
Articles in this issue
about 17 years ago
New Doxil-based regimens don’t fly with FDA advisorsabout 17 years ago
Four steps to improve the profitability of your oncology practiceabout 17 years ago
Mathematical model predicts resistance to Herceptinabout 17 years ago
ASTRO issues guide on accelerated breast radiotherapyabout 17 years ago
Study renews breast ca link to migrainesabout 17 years ago
Sutent shows promise for brain metastases in NSCLC patientsabout 17 years ago
Abraxane, carboplatin pack one-two punch in two types of lung cancerabout 17 years ago
Discord prevails over pt privacy in clinical trialsAdvertisement
Related to this article
Joshua Richter, MD, and Marco Davila, MD, PhD, discuss early evaluation, sequencing, referral partnerships, and access to CAR T-cell therapy in myeloma.
Findings may provide reassurance to patients with early-stage disease that surgery may help improve survival rates.
In a retrospective study, high AI-derived whole-body tumor volume on PSMA PET-CT was associated with a 3.20-fold higher risk of death in prostate cancer.
The FDA set a June 15, 2027, target action date for sacituzumab tirumotecan in endometrial cancer previously treated with platinum chemotherapy and immunotherapy.
Parul N. Barry, MD, FACRO, discussed building programs early in a career and used low-dose radiotherapy and aromatase inhibitor tolerance to show how to demonstrate value.
Sunnie Kim, MD, outlined how she monitors for endocrine, renal, pulmonary, and other immune-related adverse events during adjuvant durvalumab.
Rocbrutinib plus R-CHOP yielded a 100% ORR and an 86.7% CR rate in 15 patients with untreated non-GCB DLBCL, warranting randomized evaluation.
Advertisement
Advertisement
Trending on CancerNetwork
1
AI-Measured Tumor Volume on PSMA PET-CT Linked With Survival in Prostate Cancer
2
How Could Rocbrutinib Plus R-CHOP Reshape Frontline Non-GCB DLBCL Treatment?
3
Sac-TMT Earns FDA Priority Review in Pretreated Endometrial Cancer
4
Expanding Access to Advanced Radiation Services Across a Network
5